Alkermes plc (NASDAQ:ALKS) Shares Bought by RTW Investments LP

RTW Investments LP grew its position in Alkermes plc (NASDAQ:ALKS) by 13.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,557,835 shares of the company’s stock after buying an additional 903,802 shares during the quarter. Alkermes makes up approximately 3.3% of RTW Investments LP’s portfolio, making the stock its 8th largest position. RTW Investments LP’s holdings in Alkermes were worth $217,363,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of ALKS. Barclays PLC grew its stake in Alkermes by 108.8% during the 3rd quarter. Barclays PLC now owns 423,931 shares of the company’s stock valued at $11,867,000 after acquiring an additional 220,893 shares in the last quarter. Franklin Resources Inc. grew its stake in shares of Alkermes by 2.5% in the 3rd quarter. Franklin Resources Inc. now owns 120,006 shares of the company’s stock valued at $3,486,000 after buying an additional 2,903 shares in the last quarter. Wedge Capital Management L L P NC grew its stake in shares of Alkermes by 1.3% in the 4th quarter. Wedge Capital Management L L P NC now owns 111,909 shares of the company’s stock valued at $3,219,000 after buying an additional 1,455 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Alkermes by 2.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 93,532 shares of the company’s stock valued at $2,690,000 after buying an additional 2,373 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its stake in shares of Alkermes by 3.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 30,950 shares of the company’s stock valued at $890,000 after buying an additional 897 shares in the last quarter. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Alkermes Price Performance

Shares of ALKS stock opened at $31.21 on Friday. The stock has a market cap of $5.15 billion, a P/E ratio of 14.38, a price-to-earnings-growth ratio of 2.20 and a beta of 0.51. Alkermes plc has a one year low of $22.90 and a one year high of $36.45. The stock has a fifty day moving average price of $30.62 and a 200 day moving average price of $30.64.

Alkermes (NASDAQ:ALKS) last issued its earnings results on Thursday, May 1st. The company reported $0.13 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.19). The firm had revenue of $306.51 million during the quarter, compared to the consensus estimate of $307.53 million. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. The firm’s revenue for the quarter was down 12.6% compared to the same quarter last year. During the same period last year, the business earned $0.43 earnings per share. Equities research analysts anticipate that Alkermes plc will post 1.31 EPS for the current year.

Analyst Upgrades and Downgrades

ALKS has been the subject of several recent research reports. UBS Group reissued a “sector perform” rating on shares of Alkermes in a research note on Monday, April 28th. Robert W. Baird upped their target price on Alkermes from $38.00 to $41.00 and gave the stock an “outperform” rating in a research report on Friday, May 2nd. HC Wainwright reaffirmed a “neutral” rating on shares of Alkermes in a research report on Friday, May 2nd. Cantor Fitzgerald raised Alkermes to a “strong-buy” rating in a research report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on shares of Alkermes from $40.00 to $52.00 and gave the stock a “buy” rating in a research report on Thursday, March 27th. Four investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $38.33.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.